FDA Alert on Risperdal
In 2004, the Food and Drug Administration (FDA) warned Janssen Pharmaceutica that their advertising and promotional practices for Risperdal were misleading. The FDA was particularly concerned that the pharmaceutical company did not adequately address the increased risk of hyperglycemia and diabetes in patients taking the drug.
As a result of the FDA’s actions, it is now required that all manufacturers of atypical antipsychotic medications warn the public of these conditions. This FDA alert was prompted by Janssen’s 2003 letter to physicians that glossed over some of the health risks associated with Risperdal use.
Begin
Your Free Case Review Fill out the following form or call 1-866-242-0905 24 hours a day, 7 days a week for a Free Case Review. |
What is Risperdal?
